IABP-SHOCK II

Intra-aortic balloon counterpulsation in acute myocardial infarction 

complicated by cardiogenic shock (IABP-SHOCK II): 

final 12 month results of a randomised, open-label trial

The Bottom Line - July 10, 2015 - By David Slessor

Ref: IABP-SHOCK II Trial Investigators. NEJM;2012,367(14)1287-96 - DOI: 10.1056/NEJMoa1208410

"Clinical Question

In patients with acute MI and cardiogenic shock, does intraaortic balloon counterpulsation (IABP) vs. medical therapy alone improve mortality?

The Bottom Line

In patients with cardiogenic shock following acute MI, the use of IABP did not improve mortality or any longterm secondary outcome. The use of IABPs resulted in no significant increase in complications."